These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19624462)

  • 1. CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring.
    Aleil B; Léon C; Cazenave JP; Gachet C
    J Thromb Haemost; 2009 Oct; 7(10):1747-9. PubMed ID: 19624462
    [No Abstract]   [Full Text] [Related]  

  • 2. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects.
    Umemura K; Furuta T; Kondo K
    J Thromb Haemost; 2008 Aug; 6(8):1439-41. PubMed ID: 18532997
    [No Abstract]   [Full Text] [Related]  

  • 3. Clopidogrel hyporesponsiveness and the FDA boxed warning: detection and management of patients with genetic polymorphisms.
    Perry E
    Am J Health Syst Pharm; 2011 Mar; 68(6):529-32. PubMed ID: 21378302
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.
    Hulot JS; Bura A; Villard E; Azizi M; Remones V; Goyenvalle C; Aiach M; Lechat P; Gaussem P
    Blood; 2006 Oct; 108(7):2244-7. PubMed ID: 16772608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no effect on the antiplatelet action of clopidogrel.
    El-Halabi MM; Zgheib N; Mansour NM; Malli A; Ghaith OA; Mahfouz R; Alam S; Sharara AI
    J Cardiovasc Pharmacol; 2013 Jul; 62(1):41-9. PubMed ID: 23474843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
    Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
    J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.
    Kim KA; Park PW; Hong SJ; Park JY
    Clin Pharmacol Ther; 2008 Aug; 84(2):236-42. PubMed ID: 18323861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
    Brandt JT; Close SL; Iturria SJ; Payne CD; Farid NA; Ernest CS; Lachno DR; Salazar D; Winters KJ
    J Thromb Haemost; 2007 Dec; 5(12):2429-36. PubMed ID: 17900275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacogenomics of clopidogrel.
    Levitt MR; Osbun JW; Kim LJ
    World Neurosurg; 2012; 77(3-4):406-7. PubMed ID: 22366366
    [No Abstract]   [Full Text] [Related]  

  • 11. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.
    Gong IY; Crown N; Suen CM; Schwarz UI; Dresser GK; Knauer MJ; Sugiyama D; DeGorter MK; Woolsey S; Tirona RG; Kim RB
    Eur Heart J; 2012 Nov; 33(22):2856-2464a. PubMed ID: 22374717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The genetic basis of platelet responsiveness to clopidogrel. A critical review of the literature.
    Fefer P; Matetzky S
    Thromb Haemost; 2011 Aug; 106(2):203-10. PubMed ID: 21792462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects.
    Fontana P; Hulot JS; De Moerloose P; Gaussem P
    J Thromb Haemost; 2007 Oct; 5(10):2153-5. PubMed ID: 17697139
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.
    Kelly RP; Close SL; Farid NA; Winters KJ; Shen L; Natanegara F; Jakubowski JA; Ho M; Walker JR; Small DS
    Br J Clin Pharmacol; 2012 Jan; 73(1):93-105. PubMed ID: 21689142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clopidogrel pathway.
    Sangkuhl K; Klein TE; Altman RB
    Pharmacogenet Genomics; 2010 Jul; 20(7):463-5. PubMed ID: 20440227
    [No Abstract]   [Full Text] [Related]  

  • 16. CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects.
    Chan MY; Tan K; Tan HC; Huan PT; Li B; Phua QH; Lee HK; Lee CH; Low A; Becker RC; Ong WC; Richards MA; Salim A; Tai ES; Koay E
    Pharmacogenomics; 2012 Apr; 13(5):533-42. PubMed ID: 22462746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
    Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T
    Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients.
    Yang J; Zhao HD; Tan J; Ding YL; Gu ZQ; Zou JJ
    Pharmazie; 2013 Mar; 68(3):183-6. PubMed ID: 23556336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In brief: poor metabolizers of clopidogrel (plavix).
    Med Lett Drugs Ther; 2010 May; 52(1337):33. PubMed ID: 20431520
    [No Abstract]   [Full Text] [Related]  

  • 20. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.
    Tiroch KA; Sibbing D; Koch W; Roosen-Runge T; Mehilli J; Schömig A; Kastrati A
    Am Heart J; 2010 Sep; 160(3):506-12. PubMed ID: 20826260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.